UstekiRel (Ustekinumab) is a fully human IgG1κ monoclonal antibody that binds with high affinity and specificity to a shared subunit of interleukins IL-12 and IL-23, thereby inhibiting their activity in the inflammation process. UstekiRel (Ustekinumab) is produced by a recombinant cell line process. The protein has an approximate molecular weight of 148.6 KDa and exhibits multiple glycoforms.

UstekiRel (Ustekinumab) is currently indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.